Radionuklidbehandling af neuroendokrine tumorer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Radionuklidbehandling af neuroendokrine tumorer. / Mortensen, Jann; Oturai, Peter; Højgaard, Liselotte; Knigge, Ulrich; Hansen, Carsten Palnaes; Martiný, Lars; Rasmussen, Palle; Kjær, Andreas; Oturai, Peter Sandor.

In: Ugeskrift for Laeger, Vol. 172, No. 43, 25.10.2010, p. 2950-3.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mortensen, J, Oturai, P, Højgaard, L, Knigge, U, Hansen, CP, Martiný, L, Rasmussen, P, Kjær, A & Oturai, PS 2010, 'Radionuklidbehandling af neuroendokrine tumorer', Ugeskrift for Laeger, vol. 172, no. 43, pp. 2950-3.

APA

Mortensen, J., Oturai, P., Højgaard, L., Knigge, U., Hansen, C. P., Martiný, L., Rasmussen, P., Kjær, A., & Oturai, P. S. (2010). Radionuklidbehandling af neuroendokrine tumorer. Ugeskrift for Laeger, 172(43), 2950-3.

Vancouver

Mortensen J, Oturai P, Højgaard L, Knigge U, Hansen CP, Martiný L et al. Radionuklidbehandling af neuroendokrine tumorer. Ugeskrift for Laeger. 2010 Oct 25;172(43):2950-3.

Author

Mortensen, Jann ; Oturai, Peter ; Højgaard, Liselotte ; Knigge, Ulrich ; Hansen, Carsten Palnaes ; Martiný, Lars ; Rasmussen, Palle ; Kjær, Andreas ; Oturai, Peter Sandor. / Radionuklidbehandling af neuroendokrine tumorer. In: Ugeskrift for Laeger. 2010 ; Vol. 172, No. 43. pp. 2950-3.

Bibtex

@article{3891d65ee9e241e7bcb6aa95f3e787dd,
title = "Radionuklidbehandling af neuroendokrine tumorer",
abstract = "Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.",
author = "Jann Mortensen and Peter Oturai and Liselotte H{\o}jgaard and Ulrich Knigge and Hansen, {Carsten Palnaes} and Lars Martin{\'y} and Palle Rasmussen and Andreas Kj{\ae}r and Oturai, {Peter Sandor}",
year = "2010",
month = oct,
day = "25",
language = "Dansk",
volume = "172",
pages = "2950--3",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "43",

}

RIS

TY - JOUR

T1 - Radionuklidbehandling af neuroendokrine tumorer

AU - Mortensen, Jann

AU - Oturai, Peter

AU - Højgaard, Liselotte

AU - Knigge, Ulrich

AU - Hansen, Carsten Palnaes

AU - Martiný, Lars

AU - Rasmussen, Palle

AU - Kjær, Andreas

AU - Oturai, Peter Sandor

PY - 2010/10/25

Y1 - 2010/10/25

N2 - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.

AB - Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.

M3 - Tidsskriftartikel

VL - 172

SP - 2950

EP - 2953

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 43

ER -

ID: 34045116